| Autor: |
Bub, Carolina Bonet, Reis, Isabel Nagle dos, Aravechia, Maria Giselda, Santos, Leandro Dinalli, Bastos, Eduardo Peres, Kutner, José Mauro, Castilho, Lilian |
| Zdroj: |
Revista Brasileira de Hematologia e Hemoterapia; January-March 2018, Vol. 40 Issue: 1 p25-29, 5p |
| Abstrakt: |
Pre-transfusion tests, essential for the release of blood components, may be affected by drugs. Monoclonal antibodies represent a class of medications increasingly used in the clinical practice, with anti-CD38 monoclonal antibodies (daratumumab) being a promising resource in the treatment of refractory myeloma. This monoclonal antibody recognizes CD38 in myeloma cells and interferes with pre-transfusion tests by causing panreactivity in indirect antiglobulin tests thereby clinically masking alloantibodies. Dithiothreitol is a reagent that breaks disulfide bonds and effectively destroys antigenic sites for CD38 on red blood cells. This study reports the immunohematological findings of pre-transfusion tests of patients with multiple myeloma receiving daratumumab and on solutions to prevent the interference of this monoclonal antibody. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
